Lung cancer risk in relation to mephenytoin hydroxylation activity.
Benhamou
S
S
Unit of Cancer Epidemiology (INSERM U351), Institut Gustave-Roussy, Villejuif, France.
Bouchardy
C
C
Dayer
P
P
D000328:Adult; D001189:Aryl Hydrocarbon Hydroxylases; D002277:Carcinoma / Q000201:enzymology* / Q000209:etiology; D018288:Carcinoma, Small Cell / Q000201:enzymology / Q000209:etiology; D002294:Carcinoma, Squamous Cell / Q000201:enzymology / Q000209:etiology; D016022:Case-Control Studies; D065731:Cytochrome P-450 CYP2C19; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D006900:Hydroxylation; D008175:Lung Neoplasms / Q000201:enzymology* / Q000209:etiology; D008297:Male; D008617:Mephenytoin / Q000378:metabolism*; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000378:metabolism*; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects*; D044465:White People
D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D008617:Mephenytoin